Biogen biosimilar to Roche’s arthritis therapy goes under EU review
Sohel_Parvez_Haque/iStock via Getty Images


Biogen (NASDAQ:BIIB) announced Friday that the European Medicines Agency (EMA) accepted its marketing application for BIIB800, a biosimilar to Rocheâs (OTCQX:RHHBY) (OTCQX:RHHBF) arthritis therapy RoACTEMRA.
Also known as Actemra or tocilizumab, RoACTEMRA is indicated in Europe for rheumatoid arthritis, idiopathic polyarthritis, and CAT-T cell-induced cytokine release syndrome.

In addition, the monoclonal antibody is used to treat adults with COVID-19 who are under systemic corticosteroids and require respiratory support.
Biogen (BIIB) has partnered with Chinese pharmaceutical company Bio-Thera Solutions, Ltd for BIIB800.

The company has supported its Marketing Authorization Application (MAA) with Phase 3 data for BIIB800, which indicated that the biosimilar candidate outperformed tocilizumab in rheumatoid arthritis patients with inadequate response to anti-rheumatic drug methotrexate.